 |
|
Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis
Manuel Comabella, MD;
David W. Craig, BSc;
Carlos Morcillo-Suárez, BSc;
Jordi Río, MD;
Arcadi Navarro, PhD;
Marta Fernández, BSc;
Roland Martin, MD;
Xavier Montalban, MD, PhD
Arch Neurol. 2009;66(8):972-978.
Background Interferon beta is 1 of 2 first-line treatments for relapsing-remitting multiple sclerosis (MS). However, not all patients respond to interferon beta therapy, and to date there is a lack of surrogate markers that reliably correlate with responsiveness to interferon beta therapy in MS.
Objective To identify allelic variants that influence response to interferon beta therapy in patients with MS.
Design Genome-wide scan.
Setting Academic research.
Patients Two hundred patients having relapsing-remitting MS treated with interferon beta and having a follow-up period of at least 2 years were classified as responders or nonresponders to treatment based on stringent clinical criteria.
Main Outcome Measures In the first phase of the study, a pooling-based genome-wide association study of 428 867 single-nucleotide polymorphisms (SNPs) was performed in 53 responders and 53 nonresponders to interferon beta therapy. After applying several selection criteria, 383 SNPs were individually genotyped in an independent validation cohort of 49 responders and 45 nonresponders to interferon beta therapy using a different genotyping platform.
Results Eighteen SNPs had uncorrected P < .05 associated with interferon beta responder status in the validation cohort. Of these, 7 SNPs were located in genes that code for alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid–type glutamate receptor GRIA3, type 1 interferon–related proteins ADAR and IFNAR2, cell cycle–dependent protein CIT, zinc finger proteins ZFAT and ZFHX4, and guanosine triphosphatase–activating protein STARD13.
Conclusions This study supports an underlying polygenic response to interferon beta treatment in MS and highlights the importance of the glutamatergic system in patient response to interferon beta therapy.
Author Affiliations: Centre d’Esclerosi Múltiple de Catalunya, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Departament de Medicina de la Universitat Autònoma de Barcelona (Drs Comabella, Río, and Montalban and Ms Fernández), Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra (Mr Morcillo-Suárez and Dr Navarro), Instituto Nacional de Bioinformática (Mr Morcillo-Suárez), and Institució Catalana de Recerca i Estudis Avançats (Drs Navarro and Martin), Barcelona, Spain; and Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona (Mr Craig). Dr Martin is now with the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research, Center for Molecular Neurobiology Hamburg, University Medical Center Eppendorf, Hamburg, Germany.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of Neurology
Arch Neurol. 2009;66(8):929-930.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Immune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands
Tsunoda et al.
Proc. Natl. Acad. Sci. USA 2010;107:14199-14204.
ABSTRACT
| FULL TEXT
Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients
Enevold et al.
Mult Scler 2010;16:942-949.
ABSTRACT
Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy
Pappas and Oksenberg
Neurology 2010;74:S62-S69.
ABSTRACT
| FULL TEXT
|
